332 | Humans |
217 | Male |
205 | Middle Aged |
204 | Female |
185 | Aged |
107 | Adult |
94 | Parkinson Disease (drug therapy) |
91 | Parkinson Disease (physiopathology) |
81 | Parkinson Disease (genetics) |
53 | Parkinson Disease (complications) |
51 | Parkinson Disease (diagnosis) |
47 | Aged, 80 and over |
40 | Treatment Outcome |
40 | Severity of Illness Index |
37 | Antiparkinson Agents (therapeutic use) |
35 | Follow-Up Studies |
35 | Double-Blind Method |
34 | Parkinson Disease (epidemiology) |
34 | Levodopa (therapeutic use) |
27 | Parkinson Disease (therapy) |
27 | Parkinson Disease (surgery) |
25 | Risk Factors |
24 | Genotype |
24 | Animals |
24 | Age of Onset |
23 | Disease Progression |
21 | Time Factors |
20 | Parkinson Disease (psychology) |
20 | Parkinson Disease (pathology) |
20 | Diagnosis, Differential |
20 | Cohort Studies |
19 | Neuropsychological Tests |
19 | Case-Control Studies |
18 | Prospective Studies |
18 | Antiparkinson Agents (adverse effects) |
18 | Adolescent |
17 | Parkinson Disease (metabolism) |
17 | Levodopa (adverse effects) |
17 | Brain (pathology) |
16 | Neurologic Examination |
16 | Genetic Predisposition to Disease |
15 | Retrospective Studies |
15 | Nerve Tissue Proteins (genetics) |
15 | Globus Pallidus (surgery) |
15 | Genetic Predisposition to Disease (genetics) |
14 | Neuroprotective Agents (therapeutic use) |
14 | Dose-Response Relationship, Drug |
14 | Dopamine Agonists (therapeutic use) |
14 | DNA Mutational Analysis |
13 | Parkinson Disease (etiology) |
13 | Mutation (genetics) |
13 | Gene Frequency |
13 | Disability Evaluation |
12 | Predictive Value of Tests |
12 | Mutation |
12 | Essential Tremor (genetics) |
12 | Dopamine (metabolism) |
12 | Age Factors |
11 | United States |
11 | Protein-Serine-Threonine Kinases (genetics) |
11 | Longitudinal Studies |
11 | Antiparkinson Agents (administration & dosage) |
10 | Polymorphism, Single Nucleotide |
10 | Neuroprotective Agents (pharmacology) |
10 | Clinical Trials as Topic |
10 | Brain (physiopathology) |
9 | Surveys and Questionnaires |
9 | Pedigree |
9 | Parkinson Disease, Secondary (chemically induced) |
9 | Parkinson Disease (cerebrospinal fluid) |
9 | Magnetic Resonance Imaging |
9 | Dyskinesia, Drug-Induced (etiology) |
9 | Cognition Disorders (etiology) |
9 | Alleles |
8 | Transcription Factors (genetics) |
8 | Thiophenes (administration & dosage) |
8 | Tetrahydronaphthalenes (administration & dosage) |
8 | Sex Factors |
8 | Polymorphism, Single Nucleotide (genetics) |
8 | Levodopa (administration & dosage) |
8 | Haplotypes |
8 | Genetic Variation (genetics) |
8 | Drug Therapy, Combination |
8 | Drug Administration Schedule |
8 | Administration, Cutaneous |
8 | Activities of Daily Living |
7 | Tremor (physiopathology) |
7 | Tremor (etiology) |
7 | Posture |
7 | Phenotype |
7 | Parkinson Disease (ethnology) |
7 | Neurons (metabolism) |
7 | Movement Disorders (therapy) |
7 | Essential Tremor (physiopathology) |
7 | Essential Tremor (epidemiology) |
7 | Essential Tremor (complications) |
7 | Dopamine Agonists (adverse effects) |
7 | Benzothiazoles |
6 | Young Adult |
6 | United States (epidemiology) |
6 | Tremor (genetics) |
6 | Tremor (complications) |
6 | Supranuclear Palsy, Progressive (physiopathology) |
6 | Sensitivity and Specificity |
6 | Selegiline (therapeutic use) |
6 | Risk |
6 | Reproducibility of Results |
6 | Quality of Life |
6 | Proportional Hazards Models |
6 | Polymorphism, Genetic |
6 | Polymerase Chain Reaction |
6 | Odds Ratio |
6 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
6 | Genetic Testing |
6 | Gait |
6 | Dopamine Agonists (administration & dosage) |
6 | Deep Brain Stimulation (adverse effects) |
6 | Comorbidity |
6 | Brain (metabolism) |
6 | Biomarkers (cerebrospinal fluid) |
5 | alpha-Synuclein (genetics) |
5 | Tremor (diagnosis) |
5 | Tomography, X-Ray Computed |
5 | Syndrome |
5 | Stereotaxic Techniques |
5 | Reverse Transcriptase Polymerase Chain Reaction |
5 | Receptors, Dopamine (metabolism) |
5 | Prevalence |
5 | Parkinson Disease (blood) |
5 | Movement Disorders (physiopathology) |
5 | Movement Disorders (drug therapy) |
5 | Movement Disorders (diagnosis) |
5 | Mice |
5 | Genetic Variation |
5 | Functional Laterality |
5 | European Continental Ancestry Group (genetics) |
5 | Essential Tremor (diagnosis) |
5 | Ergolines (therapeutic use) |
5 | Dystonia (physiopathology) |
5 | Dystonia (etiology) |
5 | Dystonia (complications) |
5 | Deep Brain Stimulation |
5 | Deep Brain Stimulation (methods) |
5 | Cross-Sectional Studies |
5 | Cognition Disorders (diagnosis) |
5 | Child |
5 | Carrier Proteins (genetics) |
5 | Carbidopa (therapeutic use) |
5 | Carbidopa (administration & dosage) |
5 | Basal Ganglia (physiopathology) |
5 | Antipsychotic Agents (therapeutic use) |
5 | Alzheimer Disease (cerebrospinal fluid) |
4 | tau Proteins (cerebrospinal fluid) |
4 | Ubiquitin-Protein Ligases (genetics) |
4 | Tremor (therapy) |
4 | Thiazoles (pharmacology) |
4 | Supranuclear Palsy, Progressive (diagnosis) |
4 | Subthalamic Nucleus (physiopathology) |
4 | Substantia Nigra (metabolism) |
4 | Statistics, Nonparametric |
4 | Single-Blind Method |
4 | Regression Analysis |
4 | Reference Values |
4 | Randomized Controlled Trials as Topic |
4 | Psychomotor Performance (physiology) |
4 | Postural Balance |
4 | Postoperative Complications (physiopathology) |
4 | Polymorphism, Genetic (genetics) |
4 | Placebos |
4 | Pergolide |
4 | Peptide Fragments (cerebrospinal fluid) |
4 | Parkinson Disease, Secondary (diagnosis) |
4 | Parkinson Disease (rehabilitation) |
4 | Parkinson Disease (classification) |
4 | Neuroprotective Agents (adverse effects) |
4 | Neurons (pathology) |
4 | Neurons (drug effects) |
4 | Nerve Degeneration (pathology) |
4 | Multiple System Atrophy (physiopathology) |
4 | Movement |
4 | Movement Disorders (genetics) |
4 | Movement Disorders (etiology) |
4 | Mice, Inbred C57BL |
4 | Indans (therapeutic use) |
4 | Genetic Association Studies |
4 | Gait (physiology) |
4 | Functional Laterality (physiology) |
4 | Family Health |
4 | Electrodes, Implanted |
4 | Electric Stimulation |
4 | Early Diagnosis |
4 | Dopamine (physiology) |
4 | Dominance, Cerebral (physiology) |
4 | DNA-Binding Proteins (genetics) |
4 | Cell Line, Tumor |
4 | Carbidopa (adverse effects) |
4 | Canada |
4 | Apolipoproteins E (genetics) |
4 | Antiparkinson Agents (pharmacology) |
4 | Analysis of Variance |
4 | Amyloid beta-Peptides (cerebrospinal fluid) |
4 | Alzheimer Disease (genetics) |
4 | Acetylcysteine (analogs & derivatives) |
3 | alpha-Synuclein (cerebrospinal fluid) |
3 | Videotape Recording |
3 | Tremor (surgery) |
3 | Tremor (drug therapy) |
3 | Transcription Factors (metabolism) |
3 | Tomography, Emission-Computed, Single-Photon |
3 | Tocopherols (therapeutic use) |
3 | Thiazoles (therapeutic use) |
3 | Synucleins |
3 | Risk Assessment |
3 | Reaction Time (physiology) |
3 | ROC Curve |
3 | Quality of Life (psychology) |
3 | Prognosis |
3 | Posture (physiology) |
3 | Postoperative Complications (diagnosis) |
3 | Polymorphism, Single-Stranded Conformational |
3 | Peripheral Nerve Injuries |
3 | Pergolide (adverse effects) |
3 | Parkinson Disease, Secondary (pathology) |
3 | Parkinson Disease (radiography) |
3 | Parkinson Disease (enzymology) |
3 | Pallidotomy (adverse effects) |
3 | Outcome Assessment (Health Care) |
3 | Ophthalmoplegia (diagnosis) |
3 | Neurons (physiology) |
3 | Neurodegenerative Diseases (genetics) |
3 | Neoplasms (epidemiology) |
3 | Movement Disorders (surgery) |
3 | Movement (physiology) |
3 | Motor Skills (physiology) |
3 | Motor Activity (physiology) |
3 | Motor Activity (drug effects) |
3 | Models, Genetic |
3 | Models, Animal |
3 | Mental Processes (physiology) |
3 | Memory Disorders (etiology) |
3 | Membrane Proteins (genetics) |
3 | Logistic Models |
3 | Lod Score |
3 | Linkage Disequilibrium |
3 | Levodopa (pharmacology) |
3 | Isoenzymes (genetics) |
3 | Huntington Disease (complications) |
3 | Hand (physiopathology) |
3 | Globus Pallidus (physiopathology) |
3 | Globus Pallidus (pathology) |
3 | Genetic Therapy (methods) |
3 | Genetic Markers (genetics) |
3 | Genetic Linkage |
3 | Gait Disorders, Neurologic (physiopathology) |
3 | Gait Disorders, Neurologic (etiology) |
3 | Gait Disorders, Neurologic (diagnosis) |
3 | European Continental Ancestry Group |
3 | Essential Tremor (therapy) |
3 | Electric Stimulation Therapy |
3 | Dystonia (therapy) |
3 | Drug Resistance |
3 | Dopamine Plasma Membrane Transport Proteins |
3 | Dopamine Agonists (pharmacology) |
3 | Dopamine (pharmacology) |
3 | Disease Models, Animal |
3 | Depression (etiology) |
3 | Dementia (pathology) |
3 | Deep Brain Stimulation (instrumentation) |
3 | DNA-Binding Proteins (metabolism) |
3 | Cognition |
3 | Chi-Square Distribution |
3 | Cell Line |
3 | Catechol O-Methyltransferase Inhibitors |
3 | Blotting, Western |
3 | Biomarkers (metabolism) |
3 | Biomarkers (blood) |
3 | Autophagy (physiology) |
3 | Antipsychotic Agents (adverse effects) |
3 | Alzheimer Disease (diagnosis) |
2 | tau Proteins (genetics) |
2 | alpha-Synuclein |
2 | alpha-Synuclein (metabolism) |
2 | alpha-Synuclein (blood) |
2 | Weight Loss |
2 | Wakefulness (physiology) |
2 | Vitamin E (therapeutic use) |
2 | Verbal Learning (physiology) |
2 | Ventral Thalamic Nuclei |
2 | Ventral Thalamic Nuclei (physiopathology) |
2 | Ubiquitin-Protein Ligases |
2 | Ubiquitin (metabolism) |
2 | Ubiquinone (therapeutic use) |
2 | Tyrosine 3-Monooxygenase (metabolism) |
2 | Tremor (classification) |
2 | Treatment Failure |
2 | Tourette Syndrome (history) |
2 | Tourette Syndrome (complications) |
2 | Time |
2 | Tics (complications) |
2 | Thiophenes (therapeutic use) |
2 | Thiophenes (adverse effects) |
2 | Thiazoles (adverse effects) |
2 | Thalamic Nuclei (surgery) |
2 | Tetrahydronaphthalenes (therapeutic use) |
2 | Tetrahydronaphthalenes (adverse effects) |
2 | Tetrabenazine (therapeutic use) |
2 | Telephone |
2 | Supranuclear Palsy, Progressive (etiology) |
2 | Subthalamic Nucleus (physiology) |
2 | Substantia Nigra (physiopathology) |
2 | Substantia Nigra (pathology) |
2 | Statistics as Topic |
2 | Societies, Medical (standards) |
2 | Sleep Stages |
2 | Sirolimus (pharmacology) |
2 | Sialorrhea (drug therapy) |
2 | Serine (genetics) |
2 | Serbia (epidemiology) |
2 | Sequence Analysis, DNA |
2 | Reflex Sympathetic Dystrophy (etiology) |
2 | Receptors, Dopamine D2 (metabolism) |
2 | Receptors, Dopamine (drug effects) |
2 | Randomized Controlled Trials as Topic (statistics & numerical data) |
2 | Random Allocation |
2 | Radiopharmaceuticals |
2 | RNA-Binding Proteins (genetics) |
2 | Quality Control |
2 | Putamen (physiopathology) |
2 | Putamen (metabolism) |
2 | Purines (therapeutic use) |
2 | Psychosurgery |
2 | Psychiatric Status Rating Scales |
2 | Protein Kinases (genetics) |
2 | Proteasome Inhibitors |
2 | Proteasome Endopeptidase Complex (metabolism) |
2 | Propranolol (therapeutic use) |
2 | Postoperative Complications (etiology) |
2 | Positron-Emission Tomography |
2 | Point Mutation |
2 | Point Mutation (genetics) |
2 | Pilot Projects |
2 | Physical Therapy Modalities |
2 | Physical Examination |
2 | Phosphorylation |
2 | Pergolide (administration & dosage) |
2 | Patient Selection |
2 | Parkinsonian Disorders (genetics) |
2 | Parkinsonian Disorders (epidemiology) |
2 | Parkinsonian Disorders (diagnosis) |
2 | Parkinsonian Disorders (complications) |
2 | Parkinson Disease, Secondary (physiopathology) |
2 | Parkinson Disease, Secondary (drug therapy) |
2 | Parkinson Disease (radionuclide imaging) |
2 | Parkinson Disease (prevention & control) |
2 | Parkinson Disease (history) |
2 | Pallidotomy |
2 | Pallidotomy (methods) |
2 | Oncogene Proteins (cerebrospinal fluid) |
2 | Occupational Exposure (adverse effects) |
2 | North America |
2 | Neurturin (genetics) |
2 | Neuroprotective Agents (administration & dosage) |
2 | Neural Pathways (physiopathology) |
2 | Nerve Tissue Proteins (metabolism) |
2 | Nerve Degeneration |
2 | Multivariate Analysis |
2 | Multiple System Atrophy (diagnosis) |
2 | Multiple System Atrophy (cerebrospinal fluid) |
2 | Movement Disorders (complications) |
2 | Motor Skills (drug effects) |
2 | Motor Activity |
2 | Molecular Sequence Data |
2 | Mobility Limitation |
2 | Microscopy, Electron |
2 | Microsatellite Repeats |
2 | Microelectrodes |
2 | Mice, Knockout |
2 | Mental Disorders (etiology) |
2 | Memory Disorders (physiopathology) |
2 | Memory (physiology) |
2 | Manganese Poisoning (physiopathology) |
2 | Manganese (adverse effects) |
2 | Linear Models |
2 | Ligases (genetics) |
2 | Lewy Bodies (pathology) |
2 | Iron Metabolism Disorders (genetics) |
2 | Iron (metabolism) |
2 | Intracellular Signaling Peptides and Proteins (cerebrospinal fluid) |
2 | Indoles (pharmacology) |
2 | Incidence |
2 | Immunohistochemistry |
2 | Huntington Disease (genetics) |
2 | Homeodomain Proteins (genetics) |
2 | History, 18th Century |
2 | Haplotypes (genetics) |
2 | Hallucinations (chemically induced) |
2 | H-Reflex (physiology) |
2 | Glycine (genetics) |
2 | Glutathione Transferase (genetics) |
2 | Glucosylceramidase (genetics) |
2 | Globus Pallidus |
2 | Genome-Wide Association Study |
2 | Genome-Wide Association Study (methods) |
2 | Genetic Testing (methods) |
2 | Gene Frequency (genetics) |
2 | Gait Disorders, Neurologic (drug therapy) |
2 | Founder Effect |
2 | Fluorine Radioisotopes |
2 | Fetal Tissue Transplantation |
2 | Feasibility Studies |
2 | Famous Persons |
2 | Exons (genetics) |
2 | Exercise (physiology) |
2 | Executive Function (physiology) |
2 | Excitatory Amino Acid Antagonists (therapeutic use) |
2 | Europe |
2 | Essential Tremor (pathology) |
2 | Essential Tremor (classification) |
2 | Ergolines (adverse effects) |
2 | Ergolines (administration & dosage) |
2 | Enzyme Inhibitors (therapeutic use) |
2 | Electric Stimulation Therapy (methods) |
2 | Dystonia (pathology) |
2 | Dystonia (genetics) |
2 | Dystonia (drug therapy) |
2 | Dystonia (diagnosis) |
2 | Dystonia (chemically induced) |
2 | Dyskinesia, Drug-Induced (physiopathology) |
2 | Dyskinesia, Drug-Induced (epidemiology) |
2 | Dyskinesia, Drug-Induced (drug therapy) |
2 | Dyskinesia, Drug-Induced (diagnosis) |
2 | Drug Combinations |
2 | Drug Combinations (therapeutic use) |
2 | Drug Combinations (administration & dosage) |
2 | Drug Administration Routes |
2 | Dopamine Agents (therapeutic use) |
2 | Dopamine (genetics) |
2 | Dominance, Cerebral |
2 | Diagnostic Imaging |
2 | Depressive Disorder (diagnosis) |
2 | Depression (diagnosis) |
2 | Dementia (diagnosis) |
2 | DNA, Mitochondrial (genetics) |
2 | DNA Mutational Analysis (methods) |
2 | Cysteine Proteinase Inhibitors (pharmacology) |
2 | Cues |
2 | Cross-Cultural Comparison |
2 | Corpus Striatum (physiopathology) |
2 | Corpus Striatum (metabolism) |
2 | Cognition Disorders (physiopathology) |
2 | Cognition Disorders (chemically induced) |
2 | Clozapine (therapeutic use) |
2 | Chromosomes, Human, Pair 2 (genetics) |
2 | Chromosomes, Human, Pair 17 |
2 | Chromosome Mapping |
2 | Cholinergic Antagonists (therapeutic use) |
2 | Child, Preschool |
2 | Cerebral Cortex (pathology) |
2 | Cerebellar Diseases (complications) |
2 | Cell Survival (physiology) |
2 | Cell Culture Techniques |
2 | Cell Count |
2 | Carbazoles (therapeutic use) |
2 | Bulbar Palsy, Progressive (drug therapy) |
2 | Bromocriptine (therapeutic use) |
2 | Brain Tissue Transplantation |
2 | Brain (radiography) |
2 | Brain (drug effects) |
2 | Brain (anatomy & histology) |
2 | Body Mass Index |
2 | Basic Helix-Loop-Helix Transcription Factors (genetics) |
2 | Base Sequence (genetics) |
2 | Basal Ganglia (pathology) |
2 | Autopsy |
2 | Autophagy (drug effects) |
2 | Autonomic Nervous System Diseases (etiology) |
2 | Austria |
2 | Atrophy (diagnosis) |
2 | Asian Continental Ancestry Group (genetics) |
2 | Arylamine N-Acetyltransferase (genetics) |
2 | Arm |
2 | Apoptosis (drug effects) |
2 | Apomorphine (therapeutic use) |
2 | Antiparkinson Agents (classification) |
2 | Antiparkinson Agents (chemistry) |
2 | Antioxidants (therapeutic use) |
2 | Amino Acid Substitution |
2 | Adrenal Medulla (transplantation) |
2 | Activities of Daily Living (classification) |
2 | Acetylcysteine (toxicity) |
2 | Acetylcysteine (pharmacology) |
2 | Accidental Falls (statistics & numerical data) |
1 | gamma-Aminobutyric Acid (metabolism) |
1 | fms-Like Tyrosine Kinase 3 (cerebrospinal fluid) |
1 | beta 2-Microglobulin |
1 | alpha-Synuclein (biosynthesis) |
1 | Writing |
1 | Wolff-Parkinson-White Syndrome (etiology) |
1 | Welding (statistics & numerical data) |
1 | Weights and Measures |